ATE341631T1 - Methode und zusammensetzung zur förderung von osteogenese - Google Patents

Methode und zusammensetzung zur förderung von osteogenese

Info

Publication number
ATE341631T1
ATE341631T1 AT01966885T AT01966885T ATE341631T1 AT E341631 T1 ATE341631 T1 AT E341631T1 AT 01966885 T AT01966885 T AT 01966885T AT 01966885 T AT01966885 T AT 01966885T AT E341631 T1 ATE341631 T1 AT E341631T1
Authority
AT
Austria
Prior art keywords
phex
activity
phex activity
osteogenesis
osteocalcin
Prior art date
Application number
AT01966885T
Other languages
English (en)
Inventor
Guy Boileau
Original Assignee
Enobia Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enobia Pharma Inc filed Critical Enobia Pharma Inc
Application granted granted Critical
Publication of ATE341631T1 publication Critical patent/ATE341631T1/de

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24011—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral endopeptidase 24.11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6494—Neprilysin (3.4.24.11), i.e. enkephalinase or neutral-endopeptidase 24.11
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/108—Osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AT01966885T 2000-08-23 2001-08-23 Methode und zusammensetzung zur förderung von osteogenese ATE341631T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22701200P 2000-08-23 2000-08-23

Publications (1)

Publication Number Publication Date
ATE341631T1 true ATE341631T1 (de) 2006-10-15

Family

ID=22851392

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01966885T ATE341631T1 (de) 2000-08-23 2001-08-23 Methode und zusammensetzung zur förderung von osteogenese

Country Status (8)

Country Link
US (1) US7399466B2 (de)
EP (1) EP1311691B1 (de)
JP (1) JP2004506046A (de)
AT (1) ATE341631T1 (de)
AU (2) AU2001287429B2 (de)
CA (1) CA2418461A1 (de)
DE (1) DE60123635T2 (de)
WO (1) WO2002015918A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004050620A2 (en) * 2002-12-03 2004-06-17 Enobia Pharma Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex
WO2004085465A1 (en) * 2003-03-26 2004-10-07 Enobia Pharma Inc. Phex substrates and methods using same
EP3404102B1 (de) 2004-04-21 2021-08-11 Alexion Pharmaceuticals, Inc. Knochenfreisetzungskonjugate und verfahren zur verwendung davon zum zielen von proteinen auf knochen
US20070081984A1 (en) 2005-10-11 2007-04-12 Shunji Tomatsu Compositions and methods for treating hypophosphatasia
US9988620B2 (en) 2010-04-30 2018-06-05 Alexion Pharmaceuticals, Inc. Methods, compositions, and kits for the treatment of matrix mineralization disorders
EP2658979B1 (de) 2010-12-27 2018-02-14 Alexion Pharmaceuticals, Inc. Zusammensetzungen mit natriuretischen peptiden und verwendungsverfahren dafür
US10052366B2 (en) 2012-05-21 2018-08-21 Alexion Pharmaceuticsl, Inc. Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof
US10822596B2 (en) 2014-07-11 2020-11-03 Alexion Pharmaceuticals, Inc. Compositions and methods for treating craniosynostosis
EP3226891A1 (de) 2014-12-05 2017-10-11 Alexion Pharmaceuticals, Inc. Behandlung von krampfanfällen mit rekombinanter alkalischer phosphatase
US10603361B2 (en) 2015-01-28 2020-03-31 Alexion Pharmaceuticals, Inc. Methods of treating a subject with an alkaline phosphatase deficiency
JP6993961B2 (ja) 2015-08-17 2022-01-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド アルカリホスファターゼの製造
WO2017058822A1 (en) 2015-09-28 2017-04-06 Alexion Pharmaceuticals, Inc. Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia
US11400140B2 (en) 2015-10-30 2022-08-02 Alexion Pharmaceuticals, Inc. Methods for treating craniosynostosis in a patient
US11065306B2 (en) 2016-03-08 2021-07-20 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in children
WO2017173395A1 (en) 2016-04-01 2017-10-05 Alexion Pharmaceuticals, Inc. Methods for treating hypophosphatasia in adolescents and adults
KR20220162816A (ko) 2016-04-01 2022-12-08 알렉시온 파마슈티칼스, 인코포레이티드 알칼리성 포스파타아제로 근육 약화의 치료
WO2017214130A1 (en) 2016-06-06 2017-12-14 Alexion Pharmaceuticals, Inc. Metal impact on manufacturing of alkaline phosphatases
JP7018933B2 (ja) 2016-08-18 2022-02-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド 気管気管支軟化症の治療方法
CN110719786A (zh) 2017-03-31 2020-01-21 阿雷克森制药公司 用于治疗成人和青少年的低磷酸酯酶症(hpp)的方法
WO2019190752A1 (en) 2018-03-30 2019-10-03 Alexion Pharmaceuticals, Inc. Manufacturing of glycoproteins
CA3173631A1 (en) 2021-02-12 2022-08-18 Walter C. Voegtli Alkaline phosphatase polypeptides and methods of use thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0739439B2 (ja) 1989-03-16 1995-05-01 寳酒造株式会社 モノクローナル抗体及びその使用方法
JPH05232109A (ja) 1990-10-04 1993-09-07 Teijin Ltd ヒト・オステオカルシンプロ蛋白の測定方法
US5208219A (en) * 1991-02-14 1993-05-04 Celtrix Pharmaceuticals Inc. Method for inducing bone growth
JP3894381B2 (ja) 1996-04-10 2007-03-22 株式会社ペプチド研究所 抗Ｇｌｕ▲１７▼−オステオカルシン抗体
WO1998010078A2 (en) 1996-09-05 1998-03-12 Karaplis Andrew C CLONING OF FULL-LENGTH HUMAN PEX cDNA
US6413760B1 (en) * 1997-04-15 2002-07-02 Genetics Institute, Inc. Highly purified mocarhagin cobra venom protease polynucleotides endcoding same and related proteases and therapeutic uses thereof
EP1054982A2 (de) * 1998-02-11 2000-11-29 Immunex Corporation Metalloprotease-disintegrins svph3-13 und svph3-17 dns und polypeptiden
CA2262056A1 (en) * 1999-02-24 2000-08-24 Guy Boileau Composition, methods and reagents for the synthesis of a soluble form of human pex

Also Published As

Publication number Publication date
CA2418461A1 (en) 2002-02-28
EP1311691A2 (de) 2003-05-21
AU8742901A (en) 2002-03-04
DE60123635T2 (de) 2007-08-16
EP1311691B1 (de) 2006-10-04
US20050069569A1 (en) 2005-03-31
WO2002015918A2 (en) 2002-02-28
DE60123635D1 (de) 2006-11-16
AU2001287429B2 (en) 2005-08-18
JP2004506046A (ja) 2004-02-26
WO2002015918A3 (en) 2002-09-26
US7399466B2 (en) 2008-07-15

Similar Documents

Publication Publication Date Title
ATE341631T1 (de) Methode und zusammensetzung zur förderung von osteogenese
ATE517996T1 (de) Verfahren und mittel zur erhöhung der toleranz von pflanzen gegenüber stressbedingungen
ATE458731T1 (de) Pyrimidin-derivate zur behandlung von anormalem zellwachstum
DE60202727D1 (de) Inhibition von Histondeacetylase zur Behandlung von Herzhypertrophie
DE50312289D1 (de) Verfahren zur Isolierung von mesenchymalen Stammzellen des Haarfollikels
DE60132113D1 (de) Stabilisierte zusammensetzung zum enzymatischen entfernen von wundgrind
DE602004014117D1 (de) Thiazole zur verwendung als inhibitoren von protein-kinasen
DE60231395D1 (de) Dezellularisierung von gewebematrixen
DE69936102D1 (de) Verwendung von tnf-alpha inhibitoren zur behandlung von nervenwurzelschäden
MY124214A (en) Compositions for promoting crowth
DE60330161D1 (de) Rifalazil zur behandlung von infektionen mit clostridium difficile
EP1802292A4 (de) Zusammensetzungen und verfahren zur auslösung von haarwachstum
ATE275411T1 (de) Verwendung von phyllanthus zur behandlung von chronisch entzündlichen und fibrotischen prozessen
DE602004017871D1 (de) Zubereitungen zur behandlung von arthritischen erscheinungen
DK1427409T3 (da) Fremgangsmåde til behandling eller forhindring af vaskulær inflammation under brug af en eller flere sterolabssorptionsinhibitorer
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
ATE497809T1 (de) Myricitrin verbindungen zur behandlung von schlafstörungen
ATE353667T1 (de) Verwendung von proteasom-inhibitoren zur behandlung des trockenen auges
DE60237039D1 (de) Verfahren zur behandlung von rosacea und telangiectasia
ATE401078T1 (de) Die verwendung von c-kithemmern zur förderung des haarwuchses
DE60026644D1 (de) Verwendung von Ferulasäure zur Behandlung von Bluthochdruck
ATE361071T1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
DE69920015D1 (de) Verfahren zur induktion der herstellung von wachstumsfaktoren
ATE338566T1 (de) Aldosteronantagonist und cyclooxygenase-2 hemmer- kombinationstherapie zur verhinderung oder behandlung von entzündungsverwandten kardiovaskulären krankheiten
ATE423129T1 (de) Inhibitoren von lyn-verbundener signaltransduktion (last) und deren verwendung zur behandlung von prostatakrebs

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties